BioCentury | Jan 14, 2013
Company News

ExperGen, Thallion cancer news

...a 2006 deal under which Thallion licensed TLN-232 (CAP-232) from ExperGen. The court also ordered ExperGen...
...to reimburse Thallion for a portion of legal expenses. In 2010, the court ruled that ExperGen...
...caused to ExperGen, but said that it would decide on damages in future court proceedings. ExperGen...
BioCentury | Jun 21, 2010
Company News

ExperGen, Thallion cancer news

...Thallion said the International Chamber of Commerce International Court of Arbitration ruled in favor of ExperGen...
...dispute between the companies over a 2006 deal in which Thallion licensed TLN-232 (CAP-232) from ExperGen...
...kinase M2 isozyme (PKM2) was being evaluated in metastatic melanoma (see BioCentury, July 13, 2009). ExperGen Drug Development GmbH...
BioCentury | Jul 13, 2009
Company News

ExperGen, Thallion cancer news

...dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen...
...over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen in 2006. ExperGen...
...another dispute over license fees for the heptapeptide targeting pyruvate kinase M2 isozyme (PKM2) . ExperGen...
BioCentury | Jul 13, 2009
Clinical News

TT-232: Phase II suspended enrollment

...to enroll up to 49 patients due to an ongoing dispute with ExperGen Drug Development GmbH (Vienna, Austria). ExperGen...
...will re-evaluate the status of its TLN-232 program based on the outcome of the adjudication. ExperGen...
BioCentury | Jul 28, 2008
Clinical News

Miltefosine regulatory update

...to grant Orphan Drug designation for ExperGen's miltefosine to treat cutaneous T cell lymphoma (CTCL). ExperGen Drug Development GmbH...
BioCentury | Jan 21, 2008
Company News

Expergen GmbH, Thallion cancer news

...Inc. (now Thallion) licensed from Expergen in 2006 (see BioCentury, March 20, 2006). Thallion said Expergen...
...Thallion did not pay a US$200,000 license fee on time. Thallion disputed that claim, which Expergen...
...on Thallion’s close of C$0.37 on Jan. 16, the day before the deal was announced. Expergen...
BioCentury | Mar 27, 2006
Tools & Techniques

Improving on somatostatin

...overcome that limitation. CAP-232 (formerly TT-232 ) was in-licensed from Biostatin via technology transfer company ExperGen Drug Development GmbH...
BioCentury | Mar 20, 2006
Company News

Caprion, Expergen GmbH deal

...Caprion in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen for an undisclosed amount of...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...
...will receive an undisclosed payment in stock and cash. Caprion Pharmaceuticals Inc. , Montreal, Quebec Expergen...
BioCentury | Mar 15, 2006
Company News

Caprion in-licenses CAP-232

...Caprion (Montreal, Quebec) in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen (Vienna, Austria) for...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...
Items per page:
1 - 9 of 9
BioCentury | Jan 14, 2013
Company News

ExperGen, Thallion cancer news

...a 2006 deal under which Thallion licensed TLN-232 (CAP-232) from ExperGen. The court also ordered ExperGen...
...to reimburse Thallion for a portion of legal expenses. In 2010, the court ruled that ExperGen...
...caused to ExperGen, but said that it would decide on damages in future court proceedings. ExperGen...
BioCentury | Jun 21, 2010
Company News

ExperGen, Thallion cancer news

...Thallion said the International Chamber of Commerce International Court of Arbitration ruled in favor of ExperGen...
...dispute between the companies over a 2006 deal in which Thallion licensed TLN-232 (CAP-232) from ExperGen...
...kinase M2 isozyme (PKM2) was being evaluated in metastatic melanoma (see BioCentury, July 13, 2009). ExperGen Drug Development GmbH...
BioCentury | Jul 13, 2009
Company News

ExperGen, Thallion cancer news

...dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen...
...over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen in 2006. ExperGen...
...another dispute over license fees for the heptapeptide targeting pyruvate kinase M2 isozyme (PKM2) . ExperGen...
BioCentury | Jul 13, 2009
Clinical News

TT-232: Phase II suspended enrollment

...to enroll up to 49 patients due to an ongoing dispute with ExperGen Drug Development GmbH (Vienna, Austria). ExperGen...
...will re-evaluate the status of its TLN-232 program based on the outcome of the adjudication. ExperGen...
BioCentury | Jul 28, 2008
Clinical News

Miltefosine regulatory update

...to grant Orphan Drug designation for ExperGen's miltefosine to treat cutaneous T cell lymphoma (CTCL). ExperGen Drug Development GmbH...
BioCentury | Jan 21, 2008
Company News

Expergen GmbH, Thallion cancer news

...Inc. (now Thallion) licensed from Expergen in 2006 (see BioCentury, March 20, 2006). Thallion said Expergen...
...Thallion did not pay a US$200,000 license fee on time. Thallion disputed that claim, which Expergen...
...on Thallion’s close of C$0.37 on Jan. 16, the day before the deal was announced. Expergen...
BioCentury | Mar 27, 2006
Tools & Techniques

Improving on somatostatin

...overcome that limitation. CAP-232 (formerly TT-232 ) was in-licensed from Biostatin via technology transfer company ExperGen Drug Development GmbH...
BioCentury | Mar 20, 2006
Company News

Caprion, Expergen GmbH deal

...Caprion in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen for an undisclosed amount of...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...
...will receive an undisclosed payment in stock and cash. Caprion Pharmaceuticals Inc. , Montreal, Quebec Expergen...
BioCentury | Mar 15, 2006
Company News

Caprion in-licenses CAP-232

...Caprion (Montreal, Quebec) in-licensed CAP-232 ( TT-232 ) from technology transfer company Expergen (Vienna, Austria) for...
...melanoma and pancreatic cancer in the fourth quarter. Expergen is eligible for milestones and royalties. Expergen...
Items per page:
1 - 9 of 9